List view / Grid view

Biopharma

 

Turn back the clock and be healed Induced pluripotent stem cells and their future impact on drug discovery and regenerative medicine

9 May 2010 | By Paul D. Andrews, Drug Discovery Unit, College of Life Sciences, University of Dundee

They are only four years old and are getting everyone very excited; they were Science Magazine’s ‘Breakthrough of the Year 2008’ and Nature’s ‘Method of the Year 2009.’ Their discoverer, Shinya Yamanaka, shared the Lasker Award last year and is no doubt touted for a future Nobel Prize. ‘They’ are…

Digital polymerase chain reaction; new diagnostic opportunities

22 February 2010 | By

LGC is an international science-based company located in South West London. A progressive and innovative enterprise, LGC operates in socially responsible fields underpinning the health, safety and security of the public, and regulation and enforcement for UK government departments and blue chip clients. Our products and services enable our customers…

2009: A landmark year for stem cells

22 February 2010 | By

It would be fair to say that these past 12 months have been a watershed year for stem cell science. In years to come we may look back on 2009 and recognise it as the year in which nascent areas of science, medicine and technology came together to slowly nudge…

Protein PEGylation: An overview of chemistry and process considerations

22 February 2010 | By ,

Innovative drug delivery technologies are key components of drug development, with commercial and intellectual values. PEGylation is an excellent example of a delivery system that has scientific and multi-billion dollar commercial importance due to the remarkable improvement in the circulatory half lives of therapeutics, especially for proteins and peptides but…

Article 6: qPCR data analysis 2 – Controls and Troubleshooting

12 December 2009 | By

The tremendous increase in the number of laboratories using qPCR and publications relying on qPCR data are testament to the rapid uptake of this technology. When preceded by reverse transcription (RT-qPCR) it is regarded as the reference technique for validation of previously derived data such as from microarray studies and…

Combining perspectives: Multiscale integration of Stem Cell research

12 December 2009 | By

The promise of stem cell-based therapy is predicated on harnessing the plasticity of stem cell phenotypes to repair or replace damaged tissues. As technologies for detecting, isolating, modifying, and tracking stem cells improve, the very definition of what constitutes a stem cell is now an open question. Addressing this fundamental…

Next generation antibody therapeutics: Antibody fragments, dual-targeting strategies, and beyond…

9 October 2009 | By Dr Martin Scott, Molecular Cell Biologist, Biopharm R&D, GlaxoSmithKline and Dr Neil Clarke, Molecular Cell Biologist and Biology Section Leader, Biopharm R&D, GlaxoSmithKline

A multitude of novel therapeutic antibody formats based on modification of the conventional IgG format have arisen in recent years. The intensification of interest in this area reflects a pressing need for an additional repertoire of therapeutic molecules which retain the exquisite binding specificity and low intrinsic toxicity of monoclonal…

Article 5: qPCR data analysis – Amplification plots, Cq and normalisation

9 October 2009 | By

A pivotal attraction of qPCR technology is its apparent lack of complication; an assay consisting of the simple procedure of combining oligonucleotides, PCR mastermix buffer and nucleic acid template to produce a qPCR reaction is perceived as undemanding. This practical simplicity is complemented by the absence of any requirement for…

Article 4: Optimisation of the PCR step of a qPCR assay

30 July 2009 | By

The deceptive simplicity of a typical qPCR assay is an important reason for the exponential growth in the adoption of qPCR-related technologies for both research and diagnostic applications. The only requirements for obtaining ostensibly quantitative data are a mixing of primers, DNA and a mastermix, their distribution into individual tubes…

Quantitative Proteomics for Systems Biology

29 May 2009 | By

The pharmaceutical industry continues to experience a high attrition rate during the latter stages of small molecule therapeutic development, most disappointingly during the late, and highly expensive stages of Phase II and Phase III trial1. If left unchecked, it is likely that this late-stage failure in drug development will only…

Article 3: qPCR Assay Design

29 May 2009 | By

Real-time PCR (qPCR) data are reliable only if they result from a robust qPCR assay that has been carefully designed, validated and optimised. This process requires an extensive assay design procedure aimed at generating an optimum primer/probe/amplicon combination to allow accurate quantification of nucleic acids with minimum need for post-PCR…